A landmark analysis presented in JAMA and at ASN Kidney Week assessed the benefits of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors across patients with varying baseline glomerular filtration rates (eGFR) and albuminuria. The study found consistent kidney and cardiovascular protection from SGLT2 inhibitors irrespective of diabetes status, with meaningful effects across the spectrum of renal function and albumin excretion. Investigators pooled large randomized trial datasets and subgroup analyses to demonstrate that SGLT2 inhibitors reduce kidney disease progression and hospitalization for heart failure across diabetic and non‑diabetic populations, and across both low and high levels of albuminuria. The findings bolster guidelines calling for broader routine implementation of SGLT2 therapy in CKD and heart failure management. Clinicians and payers will weigh these data when defining treatment thresholds and coverage; the analysis could accelerate off‑label adoption in non‑diabetic CKD and influence prescribing patterns across nephrology and cardiology practices.